ALB and neoplasm: Nab-paclitaxel exploits albumin’s solubilizing capacity and tumor-targeting mechanisms to enhance the delivery of paclitaxel, achieving higher tumor drug concentrations and improved therapeutic responses while reducing the solvent-related toxicity common to conventional formulations.